Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (88)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (217)
  2. Department of Medicine (217)
  3. Solid Tumor Oncology Division (217)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (23)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (10)
  5. European Journal of Cancer (5)
  6. New England Journal of Medicine (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (47)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Abemaciclib in combination with therapies for patients with metastatic breast cancer: A phase 1b study
    Journal Article

    Tolaney, S. M.; Jhaveri, K.; Helsten, T.; Puhalla, S. L.; Conlin, A.; Dees, E. C.; Beeram, M.; Chapman, S. C.; Lithio, A.; Litchfield, L. M.; more...
    Frontiers in Oncology (2025)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01
    Journal Article

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas, S.; De Laurentiis, M.; Wang, S.; Martínez Jañez, N.; Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Inavolisib therapy in advanced breast cancer - The authors reply
    Correspondence

    Turner, N. C.; Thanopoulou, E.; Jhaveri, K. L.
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)
    Meeting Abstract

    George, M.; Frenel, J. S.; Cortés, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)
    Meeting Abstract

    Jhaveri, K.; Pegram, M.; Neven, P.; Curigliano, G.; Spring, L. M.; Gligorov, J.; Schlam, I.; Harbeck, N.; Juric, D.; Lim, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
    Meeting Abstract

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J.; Janni, W.; Jhaveri, K.; Mouabbi, J. A.; Brufsky, A. M.; Hamilton, E. P.; Oregan, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
    Meeting Abstract

    Montero, A. J.; Giordano, A.; Jhaveri, K.; Munster, P.; Rodon, J.; Lorusso, P.; Orr, D.; Bartolomé Arcilla, J.; Italiano, A.; Elias, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
    Meeting Abstract

    Kümmel, S.; Jhaveri, K.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2 - metastatic breast cancer
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Marme, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save